Champions Oncology Reports Record Annual Revenue of $57 Million
Champions Oncology (NASDAQ:CSBR) reported strong financial results for fiscal year 2025, achieving record annual revenue of $57 million, representing a 14% year-over-year increase. The company demonstrated significant profitability improvements with net income of $4.6 million and adjusted EBITDA income of $7.1 million, compared to an adjusted EBITDA loss in the previous year.
Key highlights include the successful launch of a high-margin data business generating $4.7 million in data license revenue, improved gross margins reaching 50% (up from 41%), and a strong cash position of $9.8 million with no debt. However, Q4 showed some challenges with revenue declining 12% to $12.3 million and an adjusted EBITDA loss of $1.2 million.
Champions Oncology (NASDAQ:CSBR) ha riportato risultati finanziari solidi per l'anno fiscale 2025, raggiungendo un ricavo annuale record di 57 milioni di dollari, con un incremento del 14% rispetto all'anno precedente. L'azienda ha mostrato significativi miglioramenti nella redditività con un utile netto di 4,6 milioni di dollari e un EBITDA rettificato di 7,1 milioni di dollari, rispetto a una perdita di EBITDA rettificato nell'anno precedente.
I punti salienti includono il successo nel lancio di un'attività di dati ad alta marginalità che ha generato 4,7 milioni di dollari di ricavi da licenze dati, margini lordi migliorati fino al 50% (rispetto al 41%) e una solida posizione di cassa di 9,8 milioni di dollari senza debiti. Tuttavia, il quarto trimestre ha mostrato alcune difficoltà con un calo dei ricavi del 12% a 12,3 milioni di dollari e una perdita di EBITDA rettificato di 1,2 milioni di dollari.
Champions Oncology (NASDAQ:CSBR) reportó sólidos resultados financieros para el año fiscal 2025, alcanzando un ingreso anual récord de 57 millones de dólares, lo que representa un aumento del 14% interanual. La compañía mostró mejoras significativas en su rentabilidad con un ingreso neto de 4,6 millones de dólares y un EBITDA ajustado de 7,1 millones de dólares, en contraste con una pérdida de EBITDA ajustado el año anterior.
Los aspectos destacados incluyen el exitoso lanzamiento de un negocio de datos de alto margen que generó 4,7 millones de dólares en ingresos por licencias de datos, márgenes brutos mejorados que alcanzaron el 50% (desde el 41%) y una sólida posición de efectivo de 9,8 millones de dólares sin deuda. Sin embargo, el cuarto trimestre presentó algunos desafíos con una disminución de ingresos del 12% a 12,3 millones de dólares y una pérdida de EBITDA ajustado de 1,2 millones de dólares.
Champions Oncology (NASDAQ:CSBR)는 2025 회계연도에 강력한 재무 실적을 보고하며 연간 매출 5700만 달러로 사상 최고치를 기록했으며, 전년 대비 14% 증가했습니다. 회사는 순이익 460만 달러와 조정 EBITDA 710만 달러를 달성하며 수익성 개선을 크게 이루었는데, 이는 전년도 조정 EBITDA 손실과 대비됩니다.
주요 성과로는 고수익 데이터 사업의 성공적인 출범으로 데이터 라이선스 수익 470만 달러를 창출했고, 총이익률이 41%에서 50%로 향상되었으며, 부채 없는 980만 달러의 강력한 현금 보유를 유지한 점이 포함됩니다. 그러나 4분기에는 매출이 12% 감소한 1230만 달러를 기록하고 조정 EBITDA 손실이 120만 달러로 나타나는 등 일부 어려움이 있었습니다.
Champions Oncology (NASDAQ:CSBR) a annoncé de solides résultats financiers pour l'exercice 2025, atteignant un chiffre d'affaires annuel record de 57 millions de dollars, soit une augmentation de 14 % par rapport à l'année précédente. La société a démontré une amélioration significative de sa rentabilité avec un bénéfice net de 4,6 millions de dollars et un EBITDA ajusté de 7,1 millions de dollars, contre une perte d'EBITDA ajusté l'année précédente.
Les points forts incluent le lancement réussi d'une activité de données à forte marge générant 4,7 millions de dollars de revenus de licences de données, une amélioration des marges brutes atteignant 50 % (contre 41 %) et une solide position de trésorerie de 9,8 millions de dollars sans dette. Cependant, le quatrième trimestre a rencontré quelques difficultés avec une baisse du chiffre d'affaires de 12 % à 12,3 millions de dollars et une perte d'EBITDA ajusté de 1,2 million de dollars.
Champions Oncology (NASDAQ:CSBR) meldete starke Finanzergebnisse für das Geschäftsjahr 2025 und erzielte einen rekordverdächtigen Jahresumsatz von 57 Millionen US-Dollar, was einer Steigerung von 14 % gegenüber dem Vorjahr entspricht. Das Unternehmen zeigte deutliche Verbesserungen in der Profitabilität mit einem Nettoeinkommen von 4,6 Millionen US-Dollar und einem bereinigten EBITDA von 7,1 Millionen US-Dollar, im Vergleich zu einem bereinigten EBITDA-Verlust im Vorjahr.
Zu den wichtigsten Highlights zählt der erfolgreiche Start eines margenstarken Daten-Geschäfts, das 4,7 Millionen US-Dollar an Datenlizenz-Einnahmen generierte, verbesserte Bruttomargen von 50 % (gegenüber 41 %) sowie eine starke Liquiditätsposition von 9,8 Millionen US-Dollar ohne Schulden. Allerdings gab es im vierten Quartal einige Herausforderungen mit einem Umsatzrückgang von 12 % auf 12,3 Millionen US-Dollar und einem bereinigten EBITDA-Verlust von 1,2 Millionen US-Dollar.
- Record annual revenue of $57 million, up 14% year-over-year
- Achieved profitability with net income of $4.6 million, compared to previous losses
- Strong adjusted EBITDA of $7.1 million, versus -$3.9 million last year
- New data licensing business generated $4.7 million in high-margin revenue
- Improved gross margin to 50% from 41% in previous year
- Healthy balance sheet with $9.8 million cash and no debt
- Operating costs decreased 9% to $52.4 million through efficiency improvements
- Q4 revenue declined 12% year-over-year to $12.3 million
- Q4 adjusted EBITDA loss of $1.2 million, down from $884,000 income last year
- Q4 gross margin contracted to 41% from 48% in prior year
- Sales and marketing expenses increased 30% in Q4
Insights
Champions Oncology achieved record $57M revenue (+14% YoY) and returned to profitability with $4.6M net income after previous year losses.
Champions Oncology has executed an impressive financial turnaround in FY2025, delivering record annual revenue of
The revenue growth stems from two key sources: a
Management's cost discipline is evident in the
The company's cash position shows material improvement, with
The outlook appears promising as management expressed confidence in continued revenue growth and accelerated monetization of their data offering in fiscal 2026, citing a "strong pipeline" heading into the new fiscal year. This transformation from a primarily service-based business to one with a growing high-margin data component suggests a potentially more scalable business model moving forward.
Total annual revenue growth of
HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025.
Fourth Quarter Financial Highlights:
Total revenue of
$12.3 million Adjusted EBITDA loss of
$1.2 million New data licensing revenue of approximately
$200,000 Operating cash flow of
$6.4 million
Fiscal Year 2025 Financial Highlights:
Record annual revenue of
$57 million , an increase of14% year-over-yearNet income of
$4.6 million Adjusted EBITDA income of
$7.1 million Data license revenue of
$4.7 million Year-end cash balance of
$9.8 million
Ronnie Morris, CEO of Champions, commented, "This past year was pivotal for the Company, as we returned to growth and profitability, launched a high-margin data business and laid the foundation for long-term value creation". Added Morris, "With a strong pipeline heading into fiscal 2026, we're confident in our ability to drive continued revenue growth and further accelerate the monetization of our data offering."
David Miller, CFO of Champions added, "Our financial turnaround in fiscal 2025 was driven by disciplined execution and operational efficiency. We delivered record adjusted EBITDA, and strengthened our balance sheet, all while investing in scalable growth. We believe we're well positioned to build on this momentum in fiscal 2026."
Fourth Quarter Financial Results
Total oncology revenue for the fourth quarter of fiscal 2025 was
For the fourth quarter of fiscal 2025, Champions reported a loss from operations of
Cost of oncology revenue was
Research and development expense was
Net cash provided by operating activities for the quarter was approximately
Year-to-Date Financial Results
Total oncology revenue for fiscal year 2025 was
For the twelve months ended April 30, 2025, Champions reported income from operations of
Cost of oncology revenue was
Research and development expense was
Net cash provided by operations was
Conference Call Information:
The Company will host a conference call today at 4:30 p.m. EST (1:30 p.m. PST) to discuss its fourth quarter financial results. To participate in the call, please call 888-506-0062 (domestic) or 973-528-0011 (international) ten minutes ahead of the call and enter the access code 792442. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 52754, or by accessing the investors section of the company's website within 72 hours.
Full details of the Company's financial results will be available on, or before, July 23, 2025 and no later than Tuesday July 29, 2025 in the Company's Form 10-K at https://www.championsoncology.com.
* Non-GAAP Financial Information
This press release contains "Non-GAAP financial measures," which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP").
A further explanation and reconciliation of these Non-GAAP financial measures is included below and in the financial tables in this release.
The Company believes that the Non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company's management uses Non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results and for internal planning and forecasting purposes. Adjusted EBITDA and Adjusted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or EPS as indicators of our operating performance or to net cash provided by operating activities as a measure of our liquidity. We believe the Company's Adjusted EBITDA and Adjusted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate Non-GAAP financial results differently, particularly related to nonrecurring, unusual items.
Adjusted EBITDA
Adjusted EBITDA represents net income (loss), or net income (loss) from operations, excluding the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.
Adjusted Net Income (Loss) and Adjusted Earnings Per Share (EPS)
Adjusted net income (loss) (if denoted) and adjusted EPS exclude the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2025 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
Media Contact
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
518 488 9026
Champions Oncology, Inc.
(Dollars in thousands)
Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (Non-GAAP) (Unaudited)
Three Months Ended April 30, | Twelve Months Ended April 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Net income (loss) - GAAP | $ | (1,834 | ) | $ | (109 | ) | $ | 4,701 | $ | (7,276 | ) | |||||
Less: | ||||||||||||||||
Stock-based compensation | $ | 131 | $ | 263 | $ | 654 | $ | 1,118 | ||||||||
Depreciation and amortization | $ | 394 | $ | 457 | $ | 1,640 | $ | 1,867 | ||||||||
Loss on equipment disposal | $ | 293 | $ | 354 | $ | 293 | $ | 435 | ||||||||
Adjusted EBITDA - Non-GAAP | $ | (1,016 | ) | $ | 965 | $ | 7,288 | $ | (3,856 | ) | ||||||
Reconciliation of GAAP EPS to Non-GAAP EPS (Unaudited)
Three Months Ended April 30, | Twelve Months Ended April 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
EPS - GAAP, basic | $ | (0.13 | ) | $ | (0.01 | ) | $ | 0.34 | $ | (0.54 | ) | |||||
Less: | ||||||||||||||||
Effect of stock-based compensation on EPS | $ | 0.01 | $ | 0.02 | $ | 0.05 | $ | 0.08 | ||||||||
Effect of depreciation and amortization on EPS | $ | 0.03 | $ | 0.03 | $ | 0.12 | $ | 0.14 | ||||||||
Effect of loss on equipment disposal on EPS | $ | 0.02 | $ | 0.03 | $ | 0.02 | $ | 0.03 | ||||||||
Adjusted EPS - basic, Non-GAAP | $ | (0.07 | ) | $ | 0.07 | $ | 0.53 | $ | (0.29 | ) | ||||||
Three Months Ended April 30, | Twelve Months Ended April 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
EPS - GAAP, diluted | $ | (0.13 | ) | $ | (0.01 | ) | $ | 0.33 | $ | (0.54 | ) | |||||
Less: | ||||||||||||||||
Effect of stock-based compensation on EPS | $ | 0.01 | $ | 0.02 | $ | 0.05 | $ | 0.08 | ||||||||
Effect of depreciation and amortization on EPS | $ | 0.03 | $ | 0.03 | $ | 0.11 | $ | 0.14 | ||||||||
Effect of loss on equipment disposal on EPS | $ | 0.02 | $ | 0.03 | $ | 0.02 | $ | 0.03 | ||||||||
Adjusted EPS - diluted, Non-GAAP | $ | (0.07 | ) | $ | 0.07 | $ | 0.51 | $ | (0.29 | ) | ||||||
Condensed Consolidated Statements of Operations (Unaudited)
Three Months Ended April 30, | Twelve Months Ended April 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Oncology revenue | $ | 12,355 | $ | 14,001 | $ | 56,944 | $ | 50,155 | ||||||||
Costs and operating expenses: | ||||||||||||||||
Cost of oncology revenue | 7,271 | 7,250 | 28,389 | 29,401 | ||||||||||||
Research and development | 1,963 | 2,049 | 6,825 | 9,544 | ||||||||||||
Sales and marketing | 2,309 | 1,776 | 7,545 | 7,064 | ||||||||||||
General and administrative | 2,525 | 2,762 | 9,339 | 11,067 | ||||||||||||
Loss on disposal of equipment | 293 | 354 | 293 | 435 | ||||||||||||
Income (loss) from operations | $ | (2,006 | ) | $ | (190 | ) | $ | 4,553 | $ | (7,356 | ) | |||||
Other income (expense), net | 42 | (1 | ) | 73 | 48 | |||||||||||
Net income (loss) before benefit for income taxes | $ | (1,964 | ) | $ | (191 | ) | $ | 4,626 | $ | (7,308 | ) | |||||
Benefit for income taxes | (130 | ) | (82 | ) | (75 | ) | (32 | ) | ||||||||
Net income (loss) | $ | (1,834 | ) | $ | (109 | ) | $ | 4,701 | $ | (7,276 | ) | |||||
Net income (loss) per common share outstanding | ||||||||||||||||
basic | $ | (0.13 | ) | $ | (0.01 | ) | $ | 0.34 | $ | (0.54 | ) | |||||
diluted | $ | (0.13 | ) | $ | (0.01 | ) | $ | 0.33 | $ | (0.54 | ) | |||||
Weighted average common shares outstanding | ||||||||||||||||
basic and diluted | 13,753,575 | 13,593,758 | 13,659,786 | 13,547,604 | ||||||||||||
and diluted | 13,753,575 | 13,593,758 | 14,266,781 | 13,547,604 | ||||||||||||
Condensed Consolidated Balance Sheets as of
April 30, 2025 | April 30, 2024 | |||||||
Cash | $ | 9,785 | $ | 2,618 | ||||
Accounts receivable | 11,234 | 9,526 | ||||||
Prepaid expenses and other current assets | 1,350 | 1,495 | ||||||
Total current assets | 22,369 | 13,639 | ||||||
Property and equipment, net | $ | 4,375 | $ | 5,721 | ||||
Operating lease right-of-use assets, net | 5,080 | 6,252 | ||||||
Other long term assets | 185 | 15 | ||||||
Goodwill | 335 | 335 | ||||||
Total assets | $ | 32,344 | $ | 25,962 | ||||
Accounts payable | 4,248 | 5,800 | ||||||
Accrued liabilities | 2,556 | 2,160 | ||||||
Current portion of operating lease liabilities | 1,471 | 1,337 | ||||||
Other current liability | 135 | 150 | ||||||
Deferred revenue | 15,443 | 12,094 | ||||||
Total current liabilities | 23,853 | 21,541 | ||||||
Non-current portion operating lease liabilities | 4,634 | 6,093 | ||||||
Other non-current liabilities | 85 | 401 | ||||||
Stockholders' equity (deficit) | 3,772 | (1,903 | ) | |||||
Total liabilities and stockholders' equity (deficit) | $ | 32,344 | $ | 26,132 | ||||
Condensed Consolidated Statements of Cash Flows (Unaudited)
Twelve Months Ended | ||||||||
2025 | 2024 | |||||||
Cash flows from operating activities: | ||||||||
Net income (loss) | $ | 4,701 | $ | (7,276 | ) | |||
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||||
Stock-based compensation expense | 654 | 1,118 | ||||||
Depreciation and amortization expense | 1,640 | 1,867 | ||||||
Operating lease right of use assets | 1,172 | 1,066 | ||||||
Net loss on disposal of equipment | 293 | 435 | ||||||
Allowance and estimated credit losses | (272 | ) | 476 | |||||
Decrease in uncertain tax position | (181 | ) | - | |||||
Changes in operating assets and liabilities | (621 | ) | (3,823 | ) | ||||
Net cash (used in) provided by operating activities | 7,386 | (6,137 | ) | |||||
Cash flows from investing activities: | ||||||||
Purchases of property and equipment | (389 | ) | (836 | ) | ||||
Net cash used in investing activities | (389 | ) | (836 | ) | ||||
Cash flows from financing activities: | ||||||||
Finance lease payments | (150 | ) | (146 | ) | ||||
Repurchases of common stock | - | (634 | ) | |||||
Proceeds from exercise of options | 320 | 253 | ||||||
Net cash provided by (used in) financing activities | 170 | (527 | ) | |||||
Increase (decrease) in cash | 7,167 | (7,500 | ) | |||||
Cash, beginning of period | 2,618 | 10,118 | ||||||
Cash, end of period | $ | 9,785 | $ | 2,618 | ||||
Non-cash investing activities: | ||||||||
Equipment purchased in accounts payable | 197 | - | ||||||
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
What was Champions Oncology's (CSBR) revenue for fiscal year 2025?
How much profit did CSBR make in fiscal year 2025?
What was Champions Oncology's Q4 2025 performance?
How much revenue did CSBR's data licensing business generate?
What is Champions Oncology's current cash position?
